SCHEMBL3485824

SCHEMBL3485824

Cc1ccc(NC(=O)CN2CCC(N(C(C)C)S(=O)(=O)c3cccc(C(F)(F)F)c3)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
LMNA P02545 3/20 0.52
HSD17B10 Q99714 1/20 0.52
POLB P06746 4/20 0.50
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
RORC P51449 5/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
TSHR P16473 1/20 0.48
TP53 P04637 1/20 0.47
UBE2M P61081 2/20 0.46
DCUN1D1 Q96GG9 2/20 0.46
DRD4 P21917 1/20 0.46
RECQL P46063 1/20 0.46
KDM4E B2RXH2 1/20 0.46
CACNA1B Q00975 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485918 0.94 TSHR (0.56) ALDH1A1LMNAHSD17B10POLBMAPT
SCHEMBL3485705 0.93 ALDH1A1 (0.54) ALDH1A1LMNAHSD17B10POLBMAPT
SCHEMBL3485688 0.93 ALDH1A1 (0.50) ALDH1A1LMNAHSD17B10POLBMAPT
SCHEMBL3485300 0.91 SMN1; SMN2 (0.52) ALDH1A1LMNAHSD17B10POLBMAPT
SCHEMBL3485926 0.91 CACNA1B (0.53) ALDH1A1LMNAHSD17B10POLBMAPT
SCHEMBL3484989 0.91 RORC (0.55) ALDH1A1LMNAHSD17B10POLBMAPT
SCHEMBL13541694 0.90 DRD4 (0.53) ALDH1A1LMNAMAPTL3MBTL1TSHR
SCHEMBL3485265 0.89 ALDH1A1 (0.47) ALDH1A1LMNAHSD17B10MAPTSMN1; SMN2
SCHEMBL3486183 0.88 LMNA (0.48) ALDH1A1LMNAHSD17B10MAPTSMN1; SMN2
SCHEMBL3759221 0.86 ALDH1A1 (0.47) ALDH1A1LMNAHSD17B10POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US claimed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US claimed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO claimed
US-8791264-B2 Benzenesulfonamide compounds and their use as blockers of calcium channels PURDUE PHARMA L.P. (US) 2014-07-29 US disclosed
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels PURDUE PHARMA L.P. (CT) 2010-01-28 US disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed
WO-2007118853-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS BLOCKERS OF CALCIUM CHANNELS EURO-CELTIQUE S.A. (LU) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022595-A1 Benzenesulfonamide Compounds and Their Use as Blockers of Calcium Channels CACNA1A, CACNA1E, CACNA1B ALDH1A1 2210/4885LMNA 1608/4885HSD17B10 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.